Inhibikase Therapeutics (NYSE:IKT) Trading Down 0.6% - What's Next?

Key Points

• Inhibikase Therapeutics' share price decreased by 0.6% during mid-day trading on Thursday, dropping to $1.53 after trading as low as $1.50.
• The company has a market capitalization of $114.01 million and a PE ratio of -0.57, indicating significant financial challenges.
• Several institutional investors have increased their stakes in Inhibikase Therapeutics, with Goldman Sachs Group Inc. raising its stake by 277.7% during the first quarter.

Inhibikase Therapeutics, Inc. (NYSE:IKT - )'s share price fell 0.6% during mid-day trading on Thursday . The company traded as low as $1.50 and last traded at $1.53. 20,281 shares were traded during mid-day trading, a decline of 89% from the average session volume of 176,419 shares. The stock had previously closed at $1.54.

Inhibikase Therapeutics Price Performance

The business's 50 day moving average is $1.65 and its two-hundred day moving average is $1.81. The firm has a market capitalization of $114.01 million, a PE ratio of -0.57 and a beta of 0.89.

Institutional Investors Weigh In On Inhibikase Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of IKT. Y Intercept Hong Kong Ltd purchased a new stake in Inhibikase Therapeutics in the first quarter valued at approximately $59,000. Blair William & Co. IL raised its stake in Inhibikase Therapeutics by 15.6% in the first quarter. Blair William & Co. IL now owns 155,953 shares of the company's stock valued at $342,000 after purchasing an additional 21,000 shares in the last quarter. ADAR1 Capital Management LLC raised its stake in Inhibikase Therapeutics by 0.4% in the first quarter. ADAR1 Capital Management LLC now owns 5,122,105 shares of the company's stock valued at $11,217,000 after purchasing an additional 19,100 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Inhibikase Therapeutics by 277.7% in the first quarter. Goldman Sachs Group Inc. now owns 166,025 shares of the company's stock valued at $364,000 after purchasing an additional 122,073 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in Inhibikase Therapeutics in the first quarter valued at approximately $255,000. 3.81% of the stock is owned by hedge funds and other institutional investors.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.